FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2328886953> ?p ?o ?g. }

• W2328886953 abstract "Developments in biotechnology, synthetic chemistry, and extraction methods have contributed significantly to provide many newer antithrombotic and anticoagulant drugs. Many of these drugs exhibit mechanisms of actions distinct from heparin and oral anticoagulants. The depolymerization of heparin has resulted in the development of LMWHs. These drugs have now attained the agent of choice status for the prophylaxis of postsurgical and medical thrombotic disorders. LMWHs are now being clinically evaluated for the treatment of established thrombosis and prevention of post-acute angioplasty occlusion and reocclusion. Many newer applications of these agents will be proposed in coming years. Synthetic and recombinant antithrombin agents, such as hirudin and hirulog, have been claimed to exhibit effective anticoagulant and antithrombotic actions. The clinical data, however, are rather limited, and additional validation studies are needed. These agents, however, provide an alternate anticoagulation approach in patients who are refractory to the actions of heparin or who developed heparin-induced thrombocytopenia. Both hirudin and peptide conjugates are undergoing extensive clinical trials throughout the world in various indications. Once validated, their optimized use will provide physicians and surgeons an alternate anticoagulant approach for heparin-compromised patients. Glycosaminoglycans, such as dermatan sulfate, heparan sulfate, and other mixtures, have been developed for various indications. These drugs, however, are relatively inferior to LMWHs for the prophylaxis of thromboembolism. Although these agents have been used for phlebitis and other indications, well-designed objective clinical trials are not available at this time. Because these agents exhibit other effects, such as the effect on smooth muscle cell proliferation, these may be of some value in the control of post-percutaneous transluminal coronary angioplasty restenosis. Several synthetic analogs of heparin and related glycosaminoglycans have also been developed. One of these agents is a synthetic pentasaccharide that represents the AT-III binding site in the heparin molecule. This agent produces a strong anti-Xa effect and is devoid of any antithrombin actions. This agent is currently being developed for the prophylaxis of thromboembolism. The synthetic pentasaccharide is devoid of any effects on platelets and thus does not produce any thrombocytopenic effects. Thus it may be useful in those patients who develop thrombocytopenia and white clot syndrome. A hypersulfated lactobionic acid analog has also been developed as an antithrombotic agent. This agent was initially found to produce its antithrombotic action via HC-II. More recent data, however, show that it also releases TFPI from endogenous sites.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2328886953 created "2016-06-24" @default.
• W2328886953 creator A5007201914 @default.
• W2328886953 creator A5007859032 @default.
• W2328886953 creator A5047210555 @default.
• W2328886953 creator A5074304553 @default.
• W2328886953 date "1994-05-01" @default.
• W2328886953 modified "2023-09-25" @default.
• W2328886953 title "Current trends in the development of anticoagulant and antithrombotic drugs" @default.
• W2328886953 cites W1560970554 @default.
• W2328886953 cites W178152663 @default.
• W2328886953 cites W1786317249 @default.
• W2328886953 cites W1886309537 @default.
• W2328886953 cites W18900301 @default.
• W2328886953 cites W1964211461 @default.
• W2328886953 cites W1965642249 @default.
• W2328886953 cites W1970619525 @default.
• W2328886953 cites W1974055703 @default.
• W2328886953 cites W1977398058 @default.
• W2328886953 cites W1981213015 @default.
• W2328886953 cites W1984367790 @default.
• W2328886953 cites W1991033611 @default.
• W2328886953 cites W1991294702 @default.
• W2328886953 cites W2002586497 @default.
• W2328886953 cites W2010978479 @default.
• W2328886953 cites W2012221269 @default.
• W2328886953 cites W2014826878 @default.
• W2328886953 cites W2015547329 @default.
• W2328886953 cites W2028906838 @default.
• W2328886953 cites W2035450957 @default.
• W2328886953 cites W2036907646 @default.
• W2328886953 cites W2037980538 @default.
• W2328886953 cites W2039017397 @default.
• W2328886953 cites W2048433937 @default.
• W2328886953 cites W2055306724 @default.
• W2328886953 cites W2057715206 @default.
• W2328886953 cites W2070179354 @default.
• W2328886953 cites W2076124315 @default.
• W2328886953 cites W2077207459 @default.
• W2328886953 cites W2085944794 @default.
• W2328886953 cites W2090279732 @default.
• W2328886953 cites W2090820816 @default.
• W2328886953 cites W2093491931 @default.
• W2328886953 cites W2117899071 @default.
• W2328886953 cites W2130213600 @default.
• W2328886953 cites W2140446341 @default.
• W2328886953 cites W2145571644 @default.
• W2328886953 cites W2162003422 @default.
• W2328886953 cites W2183285266 @default.
• W2328886953 cites W2225909296 @default.
• W2328886953 cites W2324383382 @default.
• W2328886953 cites W2333268123 @default.
• W2328886953 cites W2333865711 @default.
• W2328886953 cites W2397193403 @default.
• W2328886953 cites W2403761711 @default.
• W2328886953 cites W2405531971 @default.
• W2328886953 cites W2415944359 @default.
• W2328886953 cites W2416931062 @default.
• W2328886953 cites W2418474461 @default.
• W2328886953 cites W2443858037 @default.
• W2328886953 cites W2444073021 @default.
• W2328886953 cites W2467760069 @default.
• W2328886953 cites W2474602851 @default.
• W2328886953 cites W2474758733 @default.
• W2328886953 cites W2976315369 @default.
• W2328886953 cites W303475115 @default.
• W2328886953 cites W70359381 @default.
• W2328886953 doi "https://doi.org/10.1016/s0025-7125(16)30154-7" @default.
• W2328886953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8170266" @default.
• W2328886953 hasPublicationYear "1994" @default.
• W2328886953 type Work @default.
• W2328886953 sameAs 2328886953 @default.
• W2328886953 citedByCount "17" @default.
• W2328886953 crossrefType "journal-article" @default.
• W2328886953 hasAuthorship W2328886953A5007201914 @default.
• W2328886953 hasAuthorship W2328886953A5007859032 @default.
• W2328886953 hasAuthorship W2328886953A5047210555 @default.
• W2328886953 hasAuthorship W2328886953A5074304553 @default.
• W2328886953 hasConcept C126322002 @default.
• W2328886953 hasConcept C141071460 @default.
• W2328886953 hasConcept C177713679 @default.
• W2328886953 hasConcept C2777015399 @default.
• W2328886953 hasConcept C2777292125 @default.
• W2328886953 hasConcept C2777557582 @default.
• W2328886953 hasConcept C2778041096 @default.
• W2328886953 hasConcept C2778066728 @default.
• W2328886953 hasConcept C2778205648 @default.
• W2328886953 hasConcept C2778271848 @default.
• W2328886953 hasConcept C2779026020 @default.
• W2328886953 hasConcept C2780868729 @default.
• W2328886953 hasConcept C535046627 @default.
• W2328886953 hasConcept C71924100 @default.
• W2328886953 hasConcept C89560881 @default.
• W2328886953 hasConcept C98274493 @default.
• W2328886953 hasConceptScore W2328886953C126322002 @default.
• W2328886953 hasConceptScore W2328886953C141071460 @default.
• W2328886953 hasConceptScore W2328886953C177713679 @default.
• W2328886953 hasConceptScore W2328886953C2777015399 @default.
• W2328886953 hasConceptScore W2328886953C2777292125 @default.
• W2328886953 hasConceptScore W2328886953C2777557582 @default.

• next